1. Editor's page

   EditorialNotes Pages: 1 - 1

2. Serum cholesterol reduction with tamoxifen

   • David V. Schapira
   • Nagi B. Kumar
   • Gary H. Lyman

   Report Pages: 3 - 7

3. Nuclear polymorphism — a prognostic parameter to evaluate local recurrence of female breast cancer

   • H. R. Rosen
   • M. Stierer
   • R. Weber

   Report Pages: 9 - 13

4. Tissue polypeptide antigen in tumor cytosol: A new prognostic indicator in primary breast cancer

   • Massimo Gion
   • Riccardo Mione
   • Giuliano Bruscagnin

   Report Pages: 15 - 21

5. The somatostatin analog Sandostatin (SMS201-995) in treatment of DMBA-induced rat mammary tumors

   • G. H. Bakker
   • B. Setyono-Han
   • J. G. M. Klijn

   Report Pages: 23 - 32

6. Hormone dependence of a mouse mammary tumor line inducedin vivo by medroxyprogesterone acetate

   • Edith Kordon
   • Claudia Lanari
   • Christiane Dosne Pasqualini

   Report Pages: 33 - 43

7. Cyclical use of tamoxifen and high-dose medroxyprogesterone acetate in advanced estrogen receptor positive breast cancer

   • S. Gundersen
   • S. Kvinnsland
   • H. Høst

   Report Pages: 45 - 50

8. Megestrol acetate: Phase II study of a single daily administration in advanced breast cancer

   • Paolo Pronzato
   • Fulvio Brema
   • Riccardo Rosso

   Brief communication Pages: 51 - 54

9. Breast epithelial antigen levels and breast tumor antigen content

   • R. L. Ceriani
   • C. Chan

   Brief communication Pages: 55 - 58

10. Inter-laboratory comparison of DNA flow cytometric results from paraffin-embedded breast carcinomas

    • Olli-P. Kallioniemi
    • Heikki Joensuu
    • Timo Koivula

    Brief communication Pages: 59 - 61

11. Serum placental isoferritin and breast cancer prognosis

    • M. Stierer
    • H. R. Rosen
    • Ch. Moroz

    Correspondence Pages: 63 - 63